Mesenchymal stem cells (MSCs) have been shown to secrete exosomes that are cardioprotective. Here, we demonstrated that MSC exosome, a secreted membrane vesicle, is immunologically active. MSC exosomes induced polymyxin-resistant, MYD88-dependent secreted embryonic alkaline phosphatase (SEAP) expression in a THP1-Xblue, a THP-1 reporter cell line with an NFκB-SEAP reporter gene. In contrast to lipopolysaccharide, they induced high levels of anti-inflammatory IL10 and TGFβ1 transcript at 3 and 72 h, and much attenuated levels of pro-inflammatory IL1B, IL6, TNFA and IL12P40 transcript at 3-h. The 3-h but not 72-h induction of cytokine transcript was abrogated by MyD88 deficiency. Primary human and mouse monocytes exhibited a similar exosome-induced cytokine transcript profile. Exosome-treated THP-1 but not MyD88-deficient THP-1 cells polarized activated CD4+ T cells to CD4+CD25+FoxP3+ regulatory T cells (Tregs) at a ratio of one exosome-treated THP-1 cell to 1,000 CD4+ T cells. Infusion of MSC exosomes enhanced the survival of allogenic skin graft in mice and increased Tregs.
Get full access to this article
View all access options for this article.
References
1.
Le BlancK, FrassoniF, BallL, LocatelliF, RoelofsH, LewisI, LaninoE, SundbergB, BernardoME, et al. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet, 371:1579–1586.
2.
SatoK, OzakiK, MoriM, MuroiK and OzawaK. (2010). Mesenchymal stromal cells for graft-versus-host disease: basic aspects and clinical outcomes. J Clin Exp Hematop, 50:79–89.
3.
von BahrL, SundbergB, LonniesL, SanderB, KarbachH, HagglundH, LjungmanP, GustafssonB, KarlssonH, Le BlancK and RingdenO. (2012). Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant, 18:557–564.
4.
LaiRC, YeoRW, TanSS, ZhangB, YinY, SzeNS, ChooA and LimSK. (2013). Mesenchymal stem cell exosomes: the future MSC-based therapy? In: Mesenchymal Stem Cell Therapy. ChaseLG and VemuriMC, eds. Humana Press, New York, pp. 39–62.
5.
BurrSP, DazziF and GardenOA. (2013). Mesenchymal stromal cells and regulatory T cells: the Yin and Yang of peripheral tolerance?. Immunol Cell Biol, 91:12–18.
6.
TassoR, AugelloA, Carida’M, PostiglioneF, TibilettiMG, BernasconiB, AstigianoS, FaisF, TruiniM, CanceddaR and PennesiG. (2009). Development of sarcomas in mice implanted with mesenchymal stem cells seeded onto bioscaffolds. Carcinogenesis, 30:150–157.
7.
TassoR, IlengoC, QuartoR, CanceddaR, CaspiRR and PennesiG. (2012). Mesenchymal stem cells induce functionally active T-regulatory lymphocytes in a paracrine fashion and ameliorate experimental autoimmune uveitis. Invest Ophthalmol Vis Sci, 53:786–793.
8.
EnglishK, RyanJM, TobinL, MurphyMJ, BarryFP and MahonBP. (2009). Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25Highforkhead box P3+ regulatory T cells. Clin Exp Immunol, 156:149–160.
9.
AggarwalS and PittengerM. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105:1815–1822.
10.
LaskerMV and NairSK. (2006). Intracellular TLR signaling: a structural perspective on human disease. J Immunol, 177:11–16.
LaiRC, ArslanF, TanSS, TanB, ChooA, LeeMM, ChenTS, TehBJ, EngJK, et al. (2010). Derivation and characterization of human fetal MSCs: an alternative cell source for large-scale production of cardioprotective microparticles. J Mol Cell Cardiol, 48:1215–1224.
15.
LaiRC, ChenTS and LimSK. (2011). Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease. Regen Med, 6:481–492.
TheryC, OstrowskiM and SeguraE. (2009). Membrane vesicles as conveyors of immune responses. Nat Rev Immunol, 9:581–593.
18.
RaposoG, NijmanHW, StoorvogelW, LiejendekkerR, HardingCV, MeliefCJ and GeuzeHJ. (1996). B lymphocytes secrete antigen-presenting vesicles. J Exp Med, 183:1161–1172.
19.
ValadiH, EkstromK, BossiosA, SjostrandM, LeeJJ and LotvallJO. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol, 9:654–659.
20.
TaylorDD and Gercel-TaylorC. (2011). Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin Immunopathol, 33:441–454.
21.
BobrieA, ColomboM, RaposoG and TheryC. (2011). Exosome secretion: molecular mechanisms and roles in immune responses. Traffic, 12:1659–1668.
22.
GyorgyB, SzaboTG, PasztoiM, PalZ, MisjakP, AradiB, LaszloV, PallingerE, PapE, et al. (2011). Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci, 68:2667–2688.
23.
ChaputN and TheryC. (2011). Exosomes: immune properties and potential clinical implementations. Semin Immunopathol, 33:419–440.
24.
LianQ, LyeE, Suan YeoK, Khia Way TanE, Salto-TellezM, LiuTM, PalanisamyN, El OakleyRM, LeeEH, LimB and LimSK. (2007). Derivation of clinically compliant MSCs from CD105+, CD24- differentiated human ESCs. Stem Cells, 25:425–436.
25.
SzeSK, de KleijnDP, LaiRC, Khia Way TanE, ZhaoH, YeoKS, LowTY, LianQ, LeeCN, et al. (2007). Elucidating the secretion proteome of human embryonic stem cell-derived mesenchymal stem cells. Mol Cell Proteomics, 6:1680–1689.
26.
SuPF, LiCJ, HsuCC, BensonS, WangSY, AravindaramK, ChanSI, WuSH, YangFL, et al. (2011). Dioscorea phytocompounds enhance murine splenocyte proliferation ex vivo and improve regeneration of bone marrow cells in vivo. Evid Based Complement Alternat Med, 2011:731308
27.
QueJ, LianQ, El OakleyRM, LimB and LimSK. (2007). PI3 K/Akt/mTOR-mediated translational control regulates proliferation and differentiation of lineage-restricted RoSH stem cell lines. J Mol Signal, 2:9
KellersmannR and ZhongR. (1998). Surgical Technique for Skin Transplantation in Mice. Springer-Verlag, New York, pp. 151–154.
30.
SchwoebelF, BarsigJ, WendelA and HamacherJ. (2005). Quantitative assessment of mouse skin transplant rejection using digital photography. Lab Anim, 39:209–214.
31.
AbdiR, FiorinaP, AdraCN, AtkinsonM and SayeghMH. (2008). Immunomodulation by mesenchymal stem cells. Diabetes, 57:1759–1767.
32.
LaiRC, TanSS, TehBJ, SzeSK, ArslanF, de KleijnDP, ChooA and LimSK. (2012). Proteolytic potential of the MSC exosome proteome: implications for an exosome-mediated delivery of therapeutic proteasome. Int J Proteomics, 2012:971907
33.
TomchuckSL, ZwezdarykKJ, CoffeltSB, WatermanRS, DankaES and ScandurroAB. (2008). Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells, 26:99–107.
34.
OkamuraY, WatariM, JerudES, YoungDW, IshizakaST, RoseJ, ChowJC and StraussJF3rd. (2001). The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem, 276:10229–10233.
35.
SeriniG, Bochaton-PiallatML, RoprazP, GeinozA, BorsiL, ZardiL and GabbianiG. (1998). The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol, 142:873–881.
36.
SanjabiS, ZenewiczLA, KamanakaM and FlavellRA. (2009). Anti-inflammatory and pro-inflammatory roles of TGF-β, IL-10, and IL-22 in immunity and autoimmunity. Curr Opin Pharmacol, 9:447–453.
37.
FrankenbergerM, SternsdorfT, PechumerH, PforteA and Ziegler-HeitbrockH. (1996). Differential cytokine expression in human blood monocyte subpopulations: a polymerase chain reaction analysis. Blood, 87:373–377.
38.
MantovaniA. (2006). Macrophage diversity and polarization: in vivo veritas. Blood, 108:408–409.
39.
LaskinDL, SunilVR, GardnerCR and LaskinJD. (2011). Macrophages and tissue injury: agents of defense or destruction?. Annu Rev Pharmacol Toxicol, 51:267–288.
40.
KraaijMD, SavageNDL, van der KooijSW, KoekkoekK, WangJ, van den BergJM, OttenhoffTHM, KuijpersTW, HolmdahlR, van KootenC and GeldermanKA. (2010). Induction of regulatory T cells by macrophages is dependent on production of reactive oxygen species. Proc Natl Acad Sci, 107:17686–17691.
41.
MartinezFO, GordonS, LocatiM and MantovaniA. (2006). Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol, 177:7303–7311.
42.
CooperstockMS. (1974). Inactivation of endotoxin by polymyxin B. Antimicrob Agents Chemother, 6:422–425.
43.
BannatyneRM, HarnettNM, LeeKY and BiggarWD. (1977). Inhibition of the biologic effects of endotoxin on neutrophils by polymyxin B sulfate. J Infect Dis, 136:469–474.
44.
MillsC. (2012). M1 and m2 macrophages: oracles of health and disease. Crit Rev Immunol, 32:463–488.
45.
MantovaniA, BiswasSK, GaldieroMR, SicaA and LocatiM. (2013). Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol, 229:176–185.
46.
SavageNDL, de BoerT, WalburgKV, JoostenSA, van MeijgaardenK, GelukA and OttenhoffTHM. (2008). Human anti-inflammatory macrophages induce Foxp3+GITR+CD25+ regulatory T cells, which suppress via membrane-bound TGFβ-1. J Immunol, 181:2220–2226.
47.
CasiraghiF, PericoN and RemuzziG. (2013). Mesenchymal stromal cells to promote solid organ transplantation tolerance. Curr Opin Organ Transplant, 18:51–58.
48.
LudwigAK, KordelasL, RebmannV, RadtkeS, Felderhoff-MüserU, HornPA, BeelenD and GiebelB. (2012). Exosomes - from bench to bedside. Klin Padiatr, 224:A6
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
